Ethyl Lithospermate Reduces Lipopolysaccharide-Induced Inflammation through Inhibiting NF-κB and STAT3 Pathways in...

Area of Science:

• Pharmacology
• Immunology
• Natural Products Chemistry

Background:

• Inflammation is a complex biological response implicated in numerous diseases.
• Lipopolysaccharide (LPS) is a potent endotoxin commonly used to induce inflammatory responses in experimental models.
• RAW 264.7 murine macrophages and zebrafish are established models for studying inflammation and evaluating potential therapeutic agents.

Purpose of the Study:

• To investigate the anti-inflammatory effects of ethyl lithospermate.
• To elucidate the underlying molecular mechanisms of ethyl lithospermate's action in LPS-stimulated models.
• To evaluate efficacy in both in vitro (macrophages) and in vivo (zebrafish) systems.

Main Methods:

• Cell viability was assessed using MTT assays.
• Inflammatory cytokine production (IL-6, TNF-α) was measured by ELISA.
• Western blotting and confocal microscopy were employed to analyze key signaling proteins (NF-κB, STAT3) and their activation.
• Zebrafish models were used to assess survival rates, inflammatory cell infiltration, neutrophil migration, and gene expression via qRT-PCR.

Main Results:

• Ethyl lithospermate exhibited no toxicity at concentrations up to 100 µ mol/L.
• It significantly suppressed the release of IL-6 and TNF-α in LPS-stimulated macrophages.
• The compound reduced IκBα degradation, inhibited NF-κB p65 and p-STAT3 nuclear translocation.
• In zebrafish, ethyl lithospermate improved survival, reduced inflammatory cell infiltration and neutrophil migration, and downregulated inflammatory gene expression.

Conclusions:

• Ethyl lithospermate possesses potent anti-inflammatory effects.
• Its mechanism involves the inhibition of the NF-κB and STAT3 signaling pathways.
• These findings support ethyl lithospermate as a potential therapeutic agent for inflammatory conditions.